Company intelligence / Profile preview

VisusNano

Canterbury, Kent, United Kingdom

Ownership: Private
Development stage: Other

Overview

VisusNano has developed a biodegradable polymer-based drug-eluting intraocular lens that enables controlled, sustained release of antibiotics, anti-inflammatory, and anti-proliferative agents for prevention of postoperative complications in cataract surgery. The technology is at the pre-clinical stage with promising potential to improve surgical outcomes and reduce the need for drops or laser[1].

Therapeutic areas: Ophthalmology
Modalities: DevicePolymer-drug conjugate therapy
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on VisusNano.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VisusNano.

Explore the full profile